Royalty Pharma plc
RPRXNASDAQHealthcare● Active
$55.87
+$0.85(+1.54%)
Market Cap$24.0B
P/E Ratio—
52W High$56.07
52W Low$33.37
Royalty Pharma plc (RPRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RPRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.45B | $0.00B | $0.05B | $0.18B | $0.20B |
| G&A Expenses | $0.57B | $0.24B | $0.25B | $0.23B | $0.18B |
| Total Operating Expenses | $0.82B | $0.97B | $0.86B | $1.93B | $0.86B |
| Operating Income | $1.56B | $1.29B | $1.49B | $0.31B | $1.43B |
| Operating Margin %(computed) | 65.58% | 57.10% | 63.37% | 13.73% | 62.49% |
| Interest Income | $0.03B | $0.05B | $0.07B | $0.08B | $0.05B |
| Interest Expense | $0.31B | $0.23B | $0.19B | $0.19B | $0.17B |
| Income Before Tax | $1.32B | $1.33B | $1.70B | $0.23B | $1.24B |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.77B | $0.86B | $1.13B | $0.04B | $0.62B |
| Net Margin %(computed) | 32.42% | 37.95% | 48.20% | 1.91% | 27.07% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.33 | $1.92 | $3.41 | $0.10 | $1.49 |
| Wtd Avg Shares | 0.43B | 0.45B | 0.45B | 0.44B | 0.41B |
| EBITDA | $1.64B | $1.56B | $1.89B | $0.42B | $1.43B |
| EBITDA Margin %(computed) | 68.78% | 68.76% | 80.15% | 18.94% | 62.47% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Royalty Pharma plc data
About Royalty Pharma plc (RPRX) Income Statement
Royalty Pharma plc (RPRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RPRX reported revenue of $2.38B, gross profit of $2.38B (gross margin 100.00%), and net income of $0.77B — a net profit margin of 32.42%.
Frequently asked questions
RPRX · 4 questionsRoyalty Pharma plc (RPRX) reported revenue of $2.38B for 2025, up 5.1% year-over-year.
RPRX revenueRPRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08